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Abstract
Background: Results from epidemiologic studies on the relationship between vitamin D and breast cancer risk are
inconclusive. It is possible that vitamin D may be effective in reducing risk only of specific subtypes due to disease
heterogeneity.
Methods and Findings: In case-control and case-series analyses, we examined serum concentrations of 25-hydroxyvitamin
D (25OHD) in relation to breast cancer prognostic characteristics, including histologic grade, estrogen receptor (ER), and
molecular subtypes defined by ER, progesterone receptor (PR) and HER2, among 579 women with incident breast cancer
and 574 controls matched on age and time of blood draw enrolled in the Roswell Park Cancer Institute from 2003 to 2008.
We found that breast cancer cases had significantly lower 25OHD concentrations than controls (adjusted mean, 22.8 versus
26.2 ng/mL, p,0.001). Among premenopausal women, 25OHD concentrations were lower in those with high- versus low-
grade tumors, and ER negative versus ER positive tumors (p#0.03). Levels were lowest among women with triple-negative
cancer (17.5 ng/mL), significantly different from those with luminal A cancer (24.5 ng/mL, p=0.002). In case-control
analyses, premenopausal women with 25OHD concentrations above the median had significantly lower odds of having
triple-negative cancer (OR=0.21, 95% CI=0.08–0.53) than those with levels below the median; and every 10 ng/mL increase
in serum 25OHD concentrations was associated with a 64% lower odds of having triple-negative cancer (OR=0.36, 95%
CI=0.22–0.56). The differential associations by tumor subtypes among premenopausal women were confirmed in case-
series analyses.
Conclusion: In our analyses, higher serum levels of 25OHD were associated with reduced risk of breast cancer, with
associations strongest for high grade, ER negative or triple negative cancers in premenopausal women. With further
confirmation in large prospective studies, these findings could warrant vitamin D supplementation for reducing breast
cancer risk, particularly those with poor prognostic characteristics among premenopausal women.
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Introduction
Vitamin D is a secosteroid hormone critical to bone health and
other biological pathways [1]. Circulating 25-hydroxyvitamin D
(25OHD), the widely-used biomarker for endogenous levels of
vitamin D, as well as proxies of vitamin D exposure, such as sun
exposure and dietary and supplementary intake, have been
evaluated in relation to risk of various malignancies [2]. However,
consistent associations have only been demonstrated for colorectal
cancer [3,4]. Despite numerous experimental studies repeatedly
showing anti-neoplastic activities of vitamin D on breast cancer
[5,6], findings from epidemiologic studies and randomized trials
are not definitive [7,8,9].
It is possible that tumor heterogeneity in breast cancer may
mask associations. Clinical markers including estrogen receptor
(ER), progesterone receptor (PR) and tumor grade have long been
used to classify breast cancer subtypes associated with differential
prognosis and response to cancer therapy. These crude subtypes
PLoS ONE | www.plosone.org 1 February 2011 | Volume 6 | Issue 2 | e17251were refined by recent gene expression microarray studies, which
clustered breast tumors into five major molecular subtypes [10,11].
A validated panel of immunohistochemical (IHC) markers have
been developed to approximate the classification of these subtypes,
including luminal A (ER+ and/or PR+ and HER2-), luminal B
(ER+ and/or PR+ and either HER2+ or Ki-67+), non-luminal
HER2+ (ER-, PR-, and HER2+), basal-like (ER-, PR-, HER2-,
CK5/6+ and/or HER1+), and unclassified (ER-, PR-, HER2-,
CK5/6-, and HER1-) [12,13,14]. Several studies have shown that
reproductive risk factors differ for the particular molecular
subtypes [15,16,17]; and it is likely that relationships between
vitamin D and breast cancer risk may also vary according to
subtypes. Interestingly, in the Physicians’ Health Study, blood
levels of 1,25-dihydroxyvitamin D were strongly associated with
the risk of aggressive, but not total prostate cancer [18]. Similar
differential associations may also exist for breast cancer.
The definition of breast tumors that are ‘triple negative’, i.e.,
lack of expression of ER, PR and HER2, largely overlap with that
of basal-like tumors and is sometimes used as a proxy for the latter.
Basal-like or triple negative tumors pose a major challenge for
breast cancer treatment, because it does not repond to hormonal
therapy targeting ER or trastuzumab targeting HER2. In a recent
case-series study, women with triple negative breast cancer had the
lowest serum 25OHD concentrations compared to those with
other molecular cancer subtypes [19]. However, only 15 patients
with triple negative cancer were included in that analysis. In a
case-controls study of 579 women with primary incident breast
cancer and 574 controls matched on age and time of blood
collection, we examined serum concentrations of 25OHD at
diagnosis or enrollment, with a particular focus on associations
with breast cancer prognostic characteristics, specifically, tumor
histologic grade, ER status, and molecular subtypes characterized
by ER, PR and HER2.
Methods
Study population
Data and specimens from women with breast cancer and
healthy controls were obtained from the Data Bank and
Biorepository (DBBR) at Roswell Park Cancer Institute (RPCI).
The DBBR, as previously described [20], is a comprehensive data
and sample bank containing pretreatment biospecimens that are
rigorously collected and processed, with comprehensive clinical
and epidemiologic data. Briefly, patients newly diagnosed with
cancer at RPCI are invited to participate during their initial visit
with the surgical oncologist. After consent, blood samples are
collected (prior to any treatment, including surgery, for breast
cancer) in phlebotomy when specimens for clinical measures are
drawn, transported to the laboratory through a pneumatic tube
system, and processed within one hour of blood draw. Specimens
are maintained in liquid nitrogen until analysis. The average time
interval between the time of diagnosis and the time of blood draw
for the women in our study was 27 days.
Inclusion criteria for breast cancer cases in the study were: self-
identified as non-Hispanic white, histologically confirmed primary,
incident, female breast cancer, and no prior cancer history except
non-melanoma skin cancer. Healthy controls were identified from
family members and friends of the patients and other visitors to
RPCI or from volunteers recruited from community events, and
blood was drawn and processed at RPCI in the same manner as
the cases. For this study, controls were matched to cases on five
year age category and month of blood collection. Those who were
family members or friends of the breast cancer cases were not
included in the study. Self-administered questionnaires were used
to collect data on demographics, reproduction, medical history,
family histories of cancer, and lifestyle factors including physical
activity. Self-reported physical activity compared to same age
peers was used as an estimate for sun exposure. In addition,
questionnaire data on activities including walking, running,
cycling, and golfing were included as alternative estimates for
sun exposure. A food frequency questionnaire was administered,
and questions on supplement use were included. Ninety-two
percent (92%) of the women in this study had questionnaires
returned. Postmenopausal status in the study was defined as
women who experienced 12 consecutive months of amenorrhea,
or women who underwent bilateral salpingo-oophorectomy. This
study was approved by the Institutional Review Board at RPCI.
Clinical data and breast cancer prognostic characteristics
Patients’ clinical data, including tumor stage, histologic grade
and ER, PR and HER2 status, were obtained from a clinical
database maintained by the RPCI breast program, and supple-
mented with data from abstracted medical records and the RPCI
Tumor Registry. Because IHC of CK 5/6 or EGFR was not
routinely performed in pathology, we instead defined four
molecular subtypes in our study based on ER, PR and HER2 as
follows: luminal A (ER+ and/or PR+, HER2-), luminal B (ER+
and/or PR+, HER2+), non-luminal HER2+ (ER-, PR- and
HER2+), and triple negative (ER-, PR- and HER2-). As such, we
were not able to distinguish the basal-like and unclassified
subtypes, both of which were included in the triple negative
group in our study. However, it has been shown that the
prognostic significance of the triple negative subtype is similar to
that of the basal-like subtype [21]. ER, PR and HER2 status were
measured by IHC in pathology, and amplification of HER2 gene
was tested by fluorescence in situ hybridization (FISH) when IHC
scored 2+. Histologic grade, ER status and molecular subtypes
defined by ER, PR and HER2 were used as three independent
prognostic characteristics for breast cancer. In addition, tumor
stage was also included for analysis.
Serum 25-hydroxyvitamin D assay
Considering the potential variability of 25OHD assays, we first
tested assay performance on pilot samples in two different
laboratories both running the immunochemiluminometric assay
on the DiaSorin Liasion automated instrument. At one laboratory,
the coefficient of variation (CV) was 19%, which was considered
inappropriate for the purpose of this study. At another laboratory
(Heartland Assay, Ames, IA), the CV was 6.5%, and this
laboratory was chosen. For the entire batch of samples analyzed
for cases and controls, the CV was 8.8%.
Statistical analysis
For univariate analysis, we first compared serum 25OHD
concentrations in the healthy controls by a number of selected
factors that might affect vitamin D levels, using non-parametric
tests. To compare serum 25OHD concentrations by case-control
status or by tumor prognostic characteristics, we used a
generalized linear model controlling for age, body mass index
(BMI) and season of blood collection, which had independent
effects on serum 25OHD concentrations (p,0.05). Least square
means and standard errors of 25OHD concentrations were
derived separately for each of the tumor characteristics. Physical
activity was not associated with serum 25OHD levels after control
for BMI, and adding it to the models had little impact on the
results. Thus, results without additional adjustment for physical
activity are presented.
Vitamin D and Breast Cancer Characteristics
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prognostic characteristics, we performed two types of analyses,
including case-control analysis, where healthy controls were used
as a referent group, and case-series analysis, where women with
better prognostic characteristics (grade I/II, ER+, or luminal A
subtype) were used as a referent group and women with carcinoma
in situ (CIS) were excluded. Logistic regression was used to estimate
odds ratios (OR) and 95% confidence intervals (CI) associated with
25OHD levels. When outcomes had more than two levels,
multinomial logistic regression models were fitted. Considering
large seasonal variations of 25OHD concentrations due to change
of solar ultra-violet B intensity in the Northeastern United States
through a year, we computed season-standardized 25OHD
concentrations by locally weighted multinomial regression to
determine the cut-off points of vitamin D levels for logistic
regression, following the approach described by Ahn and
colleagues [22].
For case-control analysis, season-standardized vitamin D levels
were defined as follows: deficient (,20.0 ng/mL), insufficient
(20.0–29.9 ng/mL), and sufficient ($30.0 ng/mL). For case-series
analysis of prognostic characteristics, because the number of cases
was limited in some categories, we dichotomized season-
standardized 25OHD concentrations based on the medians in
healthy controls. In addition, we also treated season-standardized
25OHD concentrations as a continuous variable in the regression
models and computed the ORs and 95% CIs associated with an
incremental increase of 10 ng/mL of 25OHD. Because etiologic
pathways of breast cancer may differ between premenopausal and
postmenopausal women, we first performed analyses for all
women, and then stratified the analyses by menopausal status.
All analyses were performed using SAS 9.2 with two-sided
significance level of 0.05 (SAS Institute, Cary, NC).
Results
Table 1 shows serum 25OHD concentrations according to
selected demographic and lifestyle characteristics of the control
population. Younger women tended to have higher 25OHD levels
than older women, although the differences were not statistically
significant. There were apparent seasonal variations of serum
25OHD concentrations, with a peak during summer season.
Circulating 25OHD concentrations were inversely associated with
BMI, and positively associated with physical activity. Women who
had higher dietary vitamin D intake or took vitamin D
supplements had higher circulating concentrations.
The median of serum 25OHD concentrations in breast cancer
cases and controls were 22.8 ng/mL and 26.2 ng/mL, respec-
Table 1. Serum 25-hydroxyvitamin D concentrations by demographic and lifestyle characteristics among healthy controls.
Characteristics N (%)
1 Serum 25OHD, median (IQR), ng/ml P-value
2
Age, year 0.56
,50 202 (35.2) 28.3 (19.8–36.3)
50–59 169 (29.4) 27.0 (19.2–33.4)
60–69 127 (22.1) 26.8 (19.4–32.3)
$70 76 (13.2) 26.7 (19.8–33.5)
Season of blood collection ,0.001
Spring (Mar–May) 99 (17.2) 25.7 (15.9–33.2)
Summer (Jun–Aug) 175 (30.5) 30.5 (22.9–36.9)
Fall (Sep–Nov) 135 (23.5) 25.2 (19.5–32.8)
Winter (Dec–Feb) 165 (28.7) 24.7 (16.5–31.8)
BMI, kg/m
2 ,0.001
,25.0 184 (33.0) 30.7 (24.4–38.8)
25.0–29.9 198 (35.5) 27.5 (20.7–33.2)
$30.0 175 (31.4) 21.6 (15.4–28.2)
Physical activity ,0.001
More active 264 (46.2) 29.3 (22.2–36.5)
Normal 198 (34.5) 24.3 (18.8–31.9)
Less active 110 (19.2) 25.1 (16.1–33.2)
Dietary vitamin D 0.003
Q1 (,42 IU/day) 146 (25.4) 24.0 (17.8–32.2)
Q2 (42–147 IU/day) 134 (23.3) 27.3 (20.6–36.8)
Q3 (148–329 IU/day) 142 (24.7) 27.6 (20.6–32.8)
Q4 ($330 IU/day) 152 (26.5) 27.3 (21.0–37.6)
Supplementary vitamin D ,0.001
Yes 259 (45.1) 28.1 (22.2–35.0)
No 315 (54.9) 24.9 (16.6–33.0)
1For some characteristics, the numbers did not add up to the totals due to missing data.
2P-values were derived from Wilcoxon rank test for variables with two levels and Kruskal-Wallis test for variables with more than two levels. Abbreviation: IQR,
interquartile range.
doi:10.1371/journal.pone.0017251.t001
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controls were either vitamin D deficient (25.8%) or insufficient
(35.7%), and only 38.5% of them had a sufficient level of 30 ng/
mL or higher. The proportion of vitamin D deficiency was even
higher in cases (38.5%), and only a small proportion of them were
considered vitamin D sufficient (21.4%) (p,0.001). As shown in
Table 2, compared to women who were vitamin D deficient, those
with sufficient levels had a 63% reduction in odds of breast cancer
(OR=0.37, 95% CI=0.27–0.51). Every 10 ng/mL incremental
increase of 25OHD concentrations was associated with an
estimated reduction of breast cancer odds by one third
(OR=0.67, 95% CI=0.59–0.75), which was significant in both
premenopausal and postmenopausal women.
When pre- and postmenopausal women with invasive breast
cancer were considered together, there were no significant
differences in serum 25OHD concentrations by histologic grade
or ER status (data not shown). However, women with triple
negative breast cancer had the lowest vitamin D concentrations
among the 4 molecular subtypes after control for age, BMI and
season of blood collection (least square mean 6 standard error:
23.060.5, 21.361.3, 21.661.6 and 19.961.1 ng/mL for luminal
A, luminal B, non-luminal HER2+ and triple negative subtypes,
respectively, p=0.046). In addition, there was an inverse
relationship between serum 25OHD concentrations and tumor
stage (26.561.0, 23.260.5, 21.360.7 and 21.962.0 ng/mL for
stage 0 [CIS], stage I, stage II/IIIA, and stage IIIB/IIIC/IV,
respectively, p,0.001).
When stratifying by menopausal status, serum 25OHD levels
did not differ by tumor characteristics among postmenopausal
women, but there were notable differences among premenopausal
women (Table 3). Those diagnosed with invasive breast cancer,
especially late stage cancer, had significantly lower 25OHD
concentrations than those with CIS (p,0.001). Among premen-
opausal women with invasive breast cancer, those who had high
grade or ER negative cancer had lower serum 25OHD
concentrations than those with high grade or ER positive cancer
(p#0.03). Moreover, premenopausal women diagnosed with triple
negative cancer tumors had the lowest concentrations compared to
those with the other three molecular subtypes (p=0.002).
In case-control analyses, ORs and 95% CIs of breast cancer
by menopausal status and tumor prognostic characteristics are
plotted in Figure 1. Among premenopausal women, those with
25OHD concentrations above the median had significantly
reduced odds of grade III cancer (OR=0.46, 95% CI=0.29–
0.74), ER negative cancer (OR=0.34, 95% CI=0.17–0.66),
and triple negative cancer (OR=0.21, 95% CI=0.08–0.53).
Using continuous vitamin D data, an incremental increase of
10 ng/mL 25OHD concentrations was associated with about
two thirds reduction of odds of triple negative breast cancer
(OR=0.36, 95% CI=0.22–0.56) (Figure S1). Among postmen-
opausal women, higher serum vitamin D levels were associated
with reduced odds of breast cancer regardless of tumor
characteristics.
In case-series analyses, high levels of serum 25OHD were less
likely to be associated with premenopausal breast cancer with poor
prognostic characteristics than low levels (grade III versus I/II,
OR=0.45, 95% CI=0.22–0.91; ER negative versus positive,
OR=0.48, 95% CI=0.21–0.93; triple negative versus luminal A
subtype, OR=0.26, 95% CI=0.09–0.71) (Figure 2). Similar
results were also found with a 10 ng/mL incremental increase of
serum 25OHD concentrations (Figure S2). In contrast, there were
no associations of 25OHD levels with cancer prognostic
characteristics in parallel analyses among postmenopausal women
(Figures 2 and S2).
Discussion
We found that higher serum 25OHD concentrations were
associated with significantly reduced odds of both premenopausal
and postmenopausal breast cancer. Among premenopausal
women only, 25OHD concentrations were significantly lower in
women with tumors with poor prognostic characteristics (high
grade, ER negative, and triple negative) than among those with
cancers with better prognostic features. The findings support the
hypothesis that vitamin D may reduce risk of the development of a
subset of tumors with more aggressive characteristics and poorer
prognosis.
Existing evidence supports a link between vitamin D and
prognostic characteristics of breast cancer. In clinical studies,
serum 25OHD concentrations have been inversely associated with
breast cancer stage [23,24] and histologic grade [25]. In a
multiethnic cohort of breast cancer survivors, women with ER
negative breast cancer had significantly lower serum 25OHD than
those with ER positive tumors [24], and in a case-control study
with both pre- and postmenopausal women, reduced risk of breast
cancer with higher 25OHD levels was found only among women
with ER-/PR- tumors [26]. In a German case-control study of
premenopausal women, plasma 25OHD and dietary vitamin D
intake were more strongly related to ER- or PR- breast cancer
Table 2. Odds ratios and 95% confidence intervals for breast cancer by serum 25-hydroxyvitamin D levels.
Serum 25OHD levels All Premenopausal Postmenopausal
case
n( % )
control
n( % )
OR
(95% CI)
case
n( % )
control
n( % )
OR
(95% CI)
case
n( % )
control
n( % )
OR
(95% CI)
Deficient 220 (38) 156 (27) 1.00 82 (33) 74 (30) 1.00 138 (41) 82 (25) 1.00
Insufficient 241 (42) 203 (35) 0.81 (0.61–1.08) 110 (45) 83 (34) 1.13 (0.72–1.77) 131 (39) 120 (36) 0.64 (0.44–0.94)
Sufficient 118 (20) 215 (37) 0.37 (0.27–0.51) 53 (22) 88 (36) 0.57 (0.34–0.93) 65 (19) 127 (39) 0.29 (0.19–0.45)
P-value for trend ,0.001 0.03 ,0.001
Continuous per 10 ng/mL
increment
579 574 0.67 (0.59–0.75) 245 245 0.76 (0.63–0.91) 334 329 0.61 (0.52–0.72)
1Serum 25-hydroxyvitamin D (25OHD) concentrations were adjusted by the week of blood collection time in a year by locally weighted multinomial regression. The
three levels were defined as follows: deficient, ,20.0 ng/mL; insufficient, 20.0–29.9 ng/mL; sufficient, $30.0 ng/mL.
2Odds ratios (OR) ad 95% confidence intervals (CI) were adjusted for age and BMI. Further adjustment for physical activity did not significantly change the results (data
not shown).
doi:10.1371/journal.pone.0017251.t002
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our findings, among postmenopausal women from the same study,
the inverse relationships between 25OHD levels and breast cancer
risk did not differ by HR status [29]. However, there are also
studies with observed associations only for HR positive cancers
[30,31] or with null findings [32,33].
The inconsistency in results across studies could be explained by
heterogeneity in study populations, in classification of HR status,
and/or in assessment of vitamin D status (dietary intake versus
circulating 25OHD). Our patient population represents a more
contemporary patient cohort (2003–2008) with data available on
ER, PR and HER2, allowing us to refine tumor subtype
classification and to distinguish the triple negative subtype.
However, we were not able to classify the basal-like subtype due
to lack of data on basal markers CK5/6 or EGFR. Although
basal-like and triple negative phenotypes largely overlap and share
a poor prognosis, the former definition represents a more refined
group by excluding the unclassified subtype, which may behave
differently in prognosis from the basal-like subtype. Our findings
warrant validation in large prospective studies where complete
data on molecular subtypes are available.
Although the exact biological mechanisms are not clear, data
from animal experiments are concordant with our findings. Vdr
knockout mice gavaged with the carcinogen dimethylbenzanthra-
cene (DMBA) were more likely to develop ER-/PR- mammary
tumors than wild type littermates [34]. Moreover, VDR expression
were remarkably lower in ER- than in ER+ breast tumors [35],
and the elevation of VDR nuclear corepressor NCoR1 level was
particularly associated with ER negativity [36]. There are two
possible explanations for these findings. First, vitamin D may
prevent the occurrence of ER negative breast cancer by interfering
with estrogen signaling pathway, as treatment with 1,25(OH)2D
down-regulated the abundance of ER and suppressed estrogen
activity in breast cancer cells [37], and vitamin D supplementation
significantly reduced blood levels of progesterone and estradiol in
women [38]. Second, vitamin D may prevent aggressive breast
cancers by modulating the extracellular microenvironment, as
vitamin D has been shown to alter the expression of a variety genes
involved in extracelluar matrix remodeling [39,40] and to
modulate breast cancer phenotypes [41].
A limitation of our study is that only a single measurement of
vitamin D at diagnosis was used, which may not necessarily
represent vitamin D levels at the time of cancer initiation or
progression. However, in a recent study, the correlation coefficient
for measurement of 25OHD concentrations in serum samples
collected in 1994 and 2008 ranged from 0.42 to 0.52, and was 0.80
when measured 12 months apart [41], suggesting reasonable
stability of endogenous vitamin D status. Because blood samples in
our study were collected shortly after diagnosis, prior to surgery or
any adjuvant therapy, there would be little influence on vitamin D
levels from life style changes after cancer diagnosis or from
treatment.
In conclusion, our study provides compelling evidence that
endogenous vitamin D levels may be associated with the etiology
of breast cancer, particularly the triple negative subtype leading to
poor prognosis among premenopausal women. Because the risk of
triple negative breast cancer peaks before menopause, and because
vitamin D deficiency can be easily corrected by increasing sun
exposure and/or supplement intake, if our findings are confirmed
in large prospective studies for temporal causality, vitamin D may
be used as a potential cancer preventive agent against triple
negative cancers among young women.
Table 3. Serum 25-hydroxyvitamin D concentrations by prognostic characteristics in premenopausal and postmenopausal women
diagnosed with breast cancer.
Tumor characteristics All (n=579) Premenopausal women (n=245) Postmenopausal women (n=334)
N( % )
1 N( % )
1 mean ± se
2, ng/mL P-value N (%)
1 mean ± se
2, ng/mL P-value
Tumor stage ,0.001 0.23
In situ 86 (15) 42 (17) 28.961.4 44 (13) 24.861.4
I 292 (51) 95 (39) 24.860.9 197 (59) 22.360.7
II/IIIA 179 (31) 96 (39) 21.361.0 83 (25) 21.461.0
IIIB/IIIC/IV 20 (3) 11 (5) 20.062.7 9 (3) 24.463.0
Histologic grade 0.005 0.81
I/II 166 (35) 56 (29) 26.061.3 110 (40) 21.960.8
III 305 (65) 137 (71) 21.660.8 168 (60) 22.160.7
ER status 0.03 0.76
Positive 372 (76) 147 (73) 23.760.8 225 (79) 22.160.6
Negative 115 (24) 55 (27) 20.261.3 60 (21) 21.761.2
Molecular subtype 0.002 0.92
Luminal A 330 (69) 129 (64) 24.560.8 201 (71) 22.260.6
Luminal B 49 (10) 23 (11) 21.261.9 26 (9) 21.161.7
Non-luminal HER2+ 32 (6) 15 (7) 21.762.5 17 (6) 21.262.2
Triple negative 74 (15) 34 (17) 17.561.6 40 (14) 21.861.4
1Two patients with tumor stage not evaluable (TX) were excluded from analysis of stage. For the analysis of histologic grade, ER status and molecular subtype, women
with carcinoma in situ (n=86) were excluded. The numbers do not add up to the total due to missing data: histologic grade (missing n=22 or 4%), ER status (missing
n=6 or 1%), and molecular subtype (missing n=8 or 2%).
2Least square mean and standard error (se) were adjusted for age, season of blood collection, and body mass index in linear regression models. Additional adjustment
for physical activity did not significantly change the results (data not shown).
doi:10.1371/journal.pone.0017251.t003
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PLoS ONE | www.plosone.org 5 February 2011 | Volume 6 | Issue 2 | e17251Figure 1. Case-control analysis of breast cancer risk by high and low vitamin D levels. Season-standardized serum 25-hydroxyvitamin D
(25OHD) concentrations were stratified into above and below the median in healthy controls by menopausal status. Odds ratios (OR) and 95%
confidence intervals (CI) were derived from multinomial logistic regression with adjustment for age at diagnosis and BMI, and presented in groups of
tumor characteristics, where healthy controls were used as a referent group. Further adjustment for physical activity did not significantly change the
results (data not shown). The lengths of horizontal lines are indicative of confidence intervals and the dots are indicative of odds ratios, with the
corresponding odds ratios and 95% confidence interval given in numbers on the right of the Y-axis.
doi:10.1371/journal.pone.0017251.g001
Figure 2. Case-series analysis of breast cancer risk by high and low vitamin D levels. Season-standardized serum 25-hydroxyvitamin D
(25OHD) concentrations were stratified into above and below the median in healthy controls by menopausal status. Odds ratios (OR) and 95%
confidence intervals (CI) were derived from multinomial logistic regression with adjustment for age at diagnosis and BMI, and presented in groups of
tumor characteristics, where women with better prognostic characteristics (grade I/II, ER+, or luminal A subtype) were used as a referent group and
women with carcinoma in situ (CIS) were excluded. Further adjustment for physical activity did not significantly change the results (data not shown).
The lengths of horizontal lines are indicative of confidence intervals and the dots are indicative of odds ratios, with the corresponding odds ratios and
95% confidence interval given in numbers on the right of the Y-axis.
doi:10.1371/journal.pone.0017251.g002
Vitamin D and Breast Cancer Characteristics
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Figure S1 Case-control analysis of breast cancer risk by
10 ng/ml increase of vitamin D levels. Season-standardized
serum 25-hydroxyvitamin D (25OHD) concentrations were
entered into the regression models as a continuous variable. Odds
ratios (OR) and 95% confidence intervals (CI) of an incremental
increase of 10 ng/mL 25OHD were derived from multinomial
logistic regression with adjustment for age at diagnosis and BMI,
and presented in groups of tumor characteristics, where healthy
controls were used as a referent group. Further adjustment for
physical activity did not significantly change the results (data not
shown). The lengths of horizontal lines are indicative of confidence
intervals and the dots are indicative of odds ratios, with the
corresponding odds ratios and 95% confidence interval given in
numbers on the right of the Y-axis.
(TIF)
Figure S2 Case-only analysis of breast cancer risk by
10 ng/ml increase of vitamin D levels. Season-standardized
serum 25-hydroxyvitamin D (25OHD) concentrations were
entered into the regression models as a continuous variable. Odds
ratios (OR) and 95% confidence intervals (CI) of an incremental
increase of 10 ng/mL 25OHD were derived from multinomial
logistic regression with adjustment for age at diagnosis and BMI,
and presented in groups of tumor characteristics, where women
with better prognostic characteristics (grade I/II, ER+, or luminal
A subtype) were used as a referent group and women with
carcinoma in situ (CIS) were excluded. Further adjustment for
physical activity did not significantly change the results (data not
shown). The lengths of horizontal lines are indicative of confidence
intervals and the dots are indicative of odds ratios, with the
corresponding odds ratios and 95% confidence interval given in
numbers on the right of the Y-axis.
(TIF)
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